Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
Clinical Gastroenterology and Hepatology · 2024-07 · 22 (7) · 1487-1496.e12
DOI: 10.1016/j.cgh.2023.09.010 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-07. Verfasst von Jean-Frederic Colombel und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.co…. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Antibodies, Monoclonal, Humanized, Methotrexate. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, Takeda Pharmaceuticals USA Inc, Takeda Pharmaceutical Company.
Abstract (Originalsprache)
BACKGROUND & AIMS: Although biologics have revolutionized the treatment of Crohn's disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS: EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, and then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2, then 40 mg every 2 weeks), and methotrexate (15 mg weekly) in biologic-naïve patients with newly diagnosed, moderate- to high-risk CD. Endoscopic remission at week 26 (primary end point; Simple Endoscopic Score for CD ≤2), clinical remission at weeks 10 and 26 (secondary end point; Crohn's Disease Activity Index
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
- The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
- Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
- Atlanta Gastroenterology Associates, Atlanta, Georgia.
- Division of Gastroenterology, Hepatology, and Nutrition, University of Utah School of Medicine, Salt Lake City, Utah.
- Alimentiv, Inc, Western University, London, Ontario, Canada.
Förderung
- National Institutes of Health
- Takeda Pharmaceuticals USA Inc
- Takeda Pharmaceutical Company
Zitieren
APA
Colombel, J. F., Ungaro, R. C., Sands, B. E., Siegel, C. A., Wolf, D. C., Valentine, J. F., Feagan, B. G., Neustifter, B., Kadali, H., Nazarey, P., James, A., Jairath, V., & Qasim Khan, R. M. (2024). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER). Clinical Gastroenterology and Hepatology, 22(7), 1487-1496.e12. https://doi.org/10.1016/j.cgh.2023.09.010
Vancouver
Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, et al. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER). Clinical Gastroenterology and Hepatology. 2024;22(7):1487-1496.e12. doi:10.1016/j.cgh.2023.09.010
BibTeX
@article{Colombel2024,
author = {Colombel, Jean-Frederic and Ungaro, Ryan C and Sands, Bruce E and Siegel, Corey A and Wolf, Douglas C and Valentine, John F and Feagan, Brian G and Neustifter, Blue and Kadali, Harisha and Nazarey, Pradeep and James, Alexandra and Jairath, Vipul and Qasim Khan, Rana M},
title = {Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {7},
pages = {1487--1496.e12},
doi = {10.1016/j.cgh.2023.09.010}
}
EUVIMED